Xeruborbactam Oral Prodrug + Ceftibuten + Xeruborbactam Oral Prodrug Placebo + Ceftibuten Placebo
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Bacterial Infections
Conditions
Bacterial Infections
Trial Timeline
Jan 30, 2024 → Jan 5, 2025
NCT ID
NCT06079775About Xeruborbactam Oral Prodrug + Ceftibuten + Xeruborbactam Oral Prodrug Placebo + Ceftibuten Placebo
Xeruborbactam Oral Prodrug + Ceftibuten + Xeruborbactam Oral Prodrug Placebo + Ceftibuten Placebo is a phase 1 stage product being developed by Shionogi for Bacterial Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT06079775. Target conditions include Bacterial Infections.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06079775 | Phase 1 | Completed |
Competing Products
20 competing products in Bacterial Infections